…three months post-launch, finds a steady adoption of the product among surveyed rheumatologists. Just over half of rheumatologists have initiated trial on Orencia SC (abatacept) for a cohort of their patients, (up from 42% one month post-launch)… there is a little cannibalization of share from the Orencia IV formulation…
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”